BioCentury
ARTICLE | Finance

Coda’s chemogenetic control

Coda to bring chemogenetically activated gene therapy to the clinic with $19M

September 14, 2018 9:51 PM UTC

Coda Biotherapeutics Inc. could have first-mover potential in the chemogenetics space, and with a newly raised $19 million series A round, the company will move its first program toward the clinic.

Seed investors MPM Capital and Versant Ventures led the round, which closed on Sept. 12. New investors Astellas Venture Management and Novartis AG (NYSE:NVS; SIX:NOVN) also participated. ...

BCIQ Company Profiles

Coda Biotherapeutics Inc.